Downregulation of LPR1 at the blood-brain barrier in streptozotocin-induced diabetic mice

Neuropharmacology

Volumn 56, Issue 6-7, 2009, Pages 1054-1059

  Hong, Hao ^a   Liu, Li Ping ^b   Liao, Jian Ming ^a   Wang, Tong Sheng ^a   Ye, Feng Ying ^a   Wu, Jing ^a   Wang, Ying Yu ^a   Wang, Ying ^a   Li, Yong Qi ^a   Long, Yan ^a   Xia, Yuan Zheng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Amyloid peptide; Blood brain barrier; Diabetes mellitus; Low density lipoprotein receptor related protein

Indexed keywords

AMYLOID BETA PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; AMYLOID BETA PROTEIN[1-40]; LOW DENSITY LIPOPROTEIN RECEPTOR; LRP1 PROTEIN, MOUSE; PEPTIDE FRAGMENT; STREPTOZOCIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; HYPERGLYCEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RECEPTOR INTRINSIC ACTIVITY; STREPTOZOCIN DIABETES; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; EXPERIMENTAL DIABETES MELLITUS; HUMAN; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

AMYLOID BETA-PROTEIN; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; RECEPTORS, LDL; STREPTOZOCIN; TUMOR SUPPRESSOR PROTEINS;

EID: 67349230450     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.03.001     Document Type: Article

References (42)

1. Akomolafe A., Beiser A., Meigs J.B., Au R., Green R.C., Farrer L.A., Wolf P.A., and Seshadri S. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Archives of Neurology 63 (2006) 1551-1555
2. Arvanitakis Z., Wilson Z., Bienias J.L., Evans D.A., and Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Archives of Neurology 61 (2004) 661-666
3. Begley D.J., and Brightman M.W. Structural and functional aspects of the blood-brain barrier. Progress in Drug Research 61 (2003) 39-78
4. Bierhaus A., Hofmann M.A., Ziegler R., and Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovascular Research 37 (1998) 586-600
5. Biessels G.J., and Gispen W.H. The impact of diabetes on cognition: what can be learned from rodent models?. Neurobiology of Aging 1 (2005) 36-41
6. Biessels G.J., Kamal A., Urban I.J., Spruijt B.M., Erkelens D.W., and Gispen W.H. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Research 800 (1998) 125-135
7. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15 (1992) 1835-1843
8. Deane R., and Zlokovic B.V. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Current Alzheimer Research 4 (2007) 191-197
9. Deane R., Yan S.D., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A.M., Armstrong D.L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., and Zlokovic B. RAGE mediates amyloid β peptide transport across the blood-brain barrier and accumulation in brain. Nature Medicine 9 (2003) 907-913
10. Deane R., Wu Z., Sagare A., Davis J., Du Yan S., Hamm K., Xu F., Parisi M., LaRue B., Hu H.W., Spijkers P., Guo H., Song X., Lenting P.J., Van Nostrand W.E., and Zlokovic B.V. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43 (2004) 333-344
11. Deane R., Wu Z., and Zlokovic B.V. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35 11 Suppl. 1 (2004) 2628-2631
12. Deora A.A., Win T., Vanhaesebroeck B., and Lander H.M. A redox-triggered ras-effector interaction. Recruitment of phosphatidylinositol 3?-kinase to ras by redox stress. The Journal of Biological Chemistry 273 (1998) 29923-29928
13. Herz, J., 2001. The LDL receptor gene family: (un) expected signal transducers in the brain. Neuron 29, 571-581.
14. Herz J., and Strickland D.K. LRP: a multifunctional scavenger and signaling receptor. The Journal of Clinical Investigation 108 (2001) 779-784
15. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M.F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D., and Schmidt A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
16. Hong H., Lu Y., Ji Z.N., and Liu G.Q. Up-regulation of P-glycoprotein expression by glutathione depletion-induced oxidative stress in rat brain microvessel endothelial cells. Journal of Neurochemistry 98 (2006) 1465-1473
17. Huang J.S., Guh J.Y., Chen H.C., Hung W.C., Lai Y.H., and Chuang L.Y. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. Journal of Cell Biochemistry 81 (2001) 102-113
18. Huttunen H.J., Fages C., and Rauvala H. Receptor for advanced glycation endproducts (RAGE) -mediated neurite outgrowth and activation of NF-kB require the cytoplasmic domain of the receptor but different downstream signaling pathways. The Journal of Biological Chemistry 294 (1999) 19919-19924
19. Kamal A., Biessels G.J., Gispen W.H., and Ramakers G.M. Synaptic transmission changes in the pyramidal cells of the hippocampus in streptozotocin-induced diabetes mellitus in rats. Brain Research 1073-1074 (2006) 276-280
20. Kang D.E., Pietrzik C.U., Baum L., Chevallier N., Merriam D.E., Kounnas M.Z., Wagner S.L., Troncoso J.C., Kawas C.H., Katzman R., and Koo E.H. Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. The Journal of Biological Chemistry 106 (2000) 1159-1166
21. Kislinger T., Fu C., Huber B., Qu W., Taguchi A., DuYan S., Hofmann M., Yan S.F., Pischetsrieder M., Stern D., and Schmidt A.M. Nε (carboxymethyl) lysine modifications of proteins are ligands for RAGE that activate cell signaling pathways and modulate gene expression. The Journal of Biological Chemistry 274 (1999) 31740-31749
22. Lander H.L., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., and Schmidt A.M. Activation of the receptor for advanced glycation endproducts triggers a MAP Kinase pathway regulated by oxidant stress. J. Biol. Chem. 272 (1997) 17810-17814
23. Liu H., Xu X., Yang Z., Deng Y., Liu X., and Xie L. Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats. Brain Research 1123 (2006) 245-252
24. Liu Y., Liu H., Yang J., Liu X., Lu S., Wen T., Xie L., and Wang G. Increased amyloid beta-peptide (1-40) level in brain of streptozotocin-induced diabetic rats. Neuroscience 153 (2008) 796-802
25. Liu, L.P., Hong, H., Liao, J.M., Wang, T.S., Wu, J., Chen, S.S., Li, Y.Q., Long, Y., Xia, Y.Z., in press. Up-regulation of RAGE at the Blood-brain barrier in streptozotocin-induced diabetic mice. Synapse.
26. Luchsinger J.A., Reitz C., Honig L.S., Tang M.X., Shea S., and Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65 (2005) 545-551
27. Magarinos A.M., and McEwen B.S. Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proceedings of the National Academy of Sciences of the of the USA 97 (2000) 11056-11061
28. Maeng H.J., Kim M.H., Jin H.E., Shin S.M., Tsuruo T., Kim S.G., Kim D.D., Shim C.K., and Chung S.J. Functional induction of P-glycoprotein in the blood-brain barrier of streptozotocin-induced diabetic rats: evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metabolism and Disposition 35 (2007) 1996-2005
29. Peila R., Rodriguez B.L., and Launer L.J. Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51 (2002) 1256-1262
30. Qu Z.S., Tian Q., Zhou X.W., Wang X.C., Wang Q., Zhang Q., and Wang J.Z. Alteration of beta-amyloid and glutamate transporter in the brain of diabetes rats and the underlying mechanism. Acta Academiae Medicinae Sinicae 27 (2005) 708-711
31. Shuli S., Yongmei Z., Zhiwei Z., and Zhijuan J. Beta-Amyloid and its binding protein in the hippocampus of diabetic mice: effect of APP17 peptide. Neuroreport 12 (2001) 3317-3319
32. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., and Zlokovic B.V. Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. The Journal of Clinical Investigation 106 (2000) 1489-1499
33. Stern D., Yan S.D., Yan S.F., and Schmidt A.M. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Advanced Drug Delivery Reviews 54 (2002) 1615-1625
34. Sun M.K., and Alkon D.L. Link between Alzheimer's disease and diabetes. Drugs Today 42 (2006) 481-489
35. Tanzi R.E., Moir R.D., and Wagner S.L. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43 (2004) 605-608
36. Thorpe S.R., and Baynes J.W. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25 (2003) 275-281
37. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. Journal of Neurochemistry 9 (2004) 807-811
38. Zlokovic B.V., Mackic J.B., Wang L., McComb J.G., and McDonough A. Differential expression of Na, K-ATPase alpha and beta subunit isoforms at the blood-brain barrier and the choroid plexus. The Journal of Biological Chemistry 268 (1993) 8019-8025
39. Zlokovic B.V., Martel C.L., Matsubara E., McComb J.G., Zheng G., McCluskey R.T., Frangione B., and Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloidβ at the blood-brain and blood-cerebrospinal fluid barriers. Proceedings of the National Academy of Sciences of the of the USA 93 (1996) 4229-4234
40. Yamagishi S., Matsui T., and Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Current Drug Targets 8 (2007) 1138-1143
41. Yan S.D., Chen X., Schmidt A.M., Brett J., Godman G., Zou Y.S., Scott C.W., Caputo C., Frappier T., and Smith M.A. The presence of glycated tau in Alzheimer's disease: a mechanism for induction of oxidant stress. Proceedings of the National Academy of Sciences of the USA 91 (1994) 7787-7791
42. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., and Schmidt A.M. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382 (1996) 685-691